Randomized phase 2 study in platinum-resistant ovarian cancer met its prespecified hazard ratio target and primary endpoint, supporting advancement to phase 3; combination extended mean ...
CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, ...
BRAFTOVI + MEKTOVI continued to show a substantial median overall survival benefit of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback